Incretin mimetics for the management of diabetes and associated comorbidities: An overview
Innovative Medicines & Omics · 2024
DOI: 10.36922/imo.4911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovative Medicines & Omics, 2024. Verfasst von Faryal Haider und 3 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus is commonly associated with various comorbidities that aggravate the disease’s overall impact on health. The most prevalent comorbidities of diabetes include obesity, dyslipidemia, hypertension, cardiovascular conditions, and kidney diseases. Incretin mimetics, also known as glucagon-like peptide-1 receptor agonists, mimic incretin hormones to stimulate insulin release in response to food intake. These medications help lower blood glucose by increasing insulin production, reducing glucagon secretion, slowing stomach emptying, and promoting satiety. A key advantage of incretin mimetics is their ability to reduce blood glucose levels without causing hypoglycemia, making them a safer option for many patients. They also promote weight loss, which is particularly beneficial for patients with both obesity and diabetes. Incretin mimetics are typically administered once or twice daily and are often used in combination with other treatments such as metformin or insulin. Evidence suggests that these drugs may reduce the risk of heart attack and stroke, an important consideration given the heightened cardiovascular risk in patients with diabetes. Additionally, incretin mimetics may help preserve pancreatic beta-cell function, potentially slowing the progression of diabetes. However, these drugs are costly and may be unaffordable for low-income individuals. Commonly reported side effects include nausea, vomiting, and diarrhea, which tend to decrease over time. While there have been reports of pancreatitis, current research indicates that incretin mimetics do not increase the risk of pancreatic cancer. Educating patients on proper use and potential side effects is crucial to ensure safe and effective treatment with incretin mimetics.
Zitieren
APA
Haider, F., Imam, S. M., Tulp, O. L., & Rizvi, S. A. A. (2024). Incretin mimetics for the management of diabetes and associated comorbidities: An overview. Innovative Medicines & Omics. https://doi.org/10.36922/imo.4911
Vancouver
Haider F, Imam SM, Tulp OL, Rizvi SAA. Incretin mimetics for the management of diabetes and associated comorbidities: An overview. Innovative Medicines & Omics. 2024. doi:10.36922/imo.4911
BibTeX
@article{Haider2024,
author = {Haider, Faryal and Imam, Syed M. and Tulp, Orien L. and Rizvi, Syed A. A.},
title = {Incretin mimetics for the management of diabetes and associated comorbidities: An overview},
journal = {Innovative Medicines & Omics},
year = {2024},
doi = {10.36922/imo.4911}
}
EUVIMED